Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UTRECHT, The Netherlands, March 06, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen & Co. 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 10:00 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.
Contacts:
Investors:
Kimberly Minarovich
+1 646 368 8014
[email protected]
Media:
David Rosen
+1 212-600-1902
[email protected]
